Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05313087 · ClinicalTrials.gov registry record
COVID-19 Vaccine Response in Chronic Respiratory Conditions
A clinical trial, sponsored by National Jewish Health.
- Completed
- Registry status
- 360
- Enrollment target
NCT05313087: Completed study, sponsored by National Jewish Health.
NCT05313087 is a clinical trial that has completed, run by National Jewish Health. The registered enrollment target is 360 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05313087 has completed, sponsored by National Jewish Health.
- COMPLETED
- Registry status
- 360 participants
- Enrollment target
Study Summary
The investigators will assess the antibody, T cell and B cell responses to SARS-CoV-2 vaccination before and every 3 months for 18 months after the initial vaccination or subsequent vaccinations (boosters) in adults and children including patients with chronic medical conditions.
Primary Outcome
quantitative spike protein antibody, binding antibody units (BAU)
Interventions
- BIOLOGICAL COVID-19 vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2021-02-03 |
| Est. Completion | 2023-12-30 |
What the finished NCT05313087 record still lists
NCT05313087 is an observational study that tracks outcomes without assigning an intervention. The registered 360 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which COVID-19 vaccine is the first listed.
NCT05313087 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05313087 about?
NCT05313087 is a clinical study titled "COVID-19 Vaccine Response in Chronic Respiratory Conditions". The investigators will assess the antibody, T cell and B cell responses to SARS-CoV-2 vaccination before and every 3 months for 18 months after the initial vaccination or subsequent vaccinations (boosters) in adults and children including patients with chronic medical conditions.
What is the current status of trial NCT05313087?
This trial is currently completed. The enrollment target is 360 participants. The study started on 2021-02-03. Estimated completion is 2023-12-30.
What interventions are being tested in trial NCT05313087?
The interventions under investigation include: COVID-19 vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT05313087?
This trial is sponsored by National Jewish Health, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02747836 · 360 participants
Ultrasound Analysis of Human Carpal Tunnel System
- NCT04089046 · 360 participants · NA
Telemedicine Enhanced Asthma Management - Uniting Providers for Teens (TEAM-UP for Teens)
- NCT04130503 · 360 participants · NA
The Recovery in Stroke Using PAP Study
- NCT04160000 · 360 participants · Phase 4
Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI